We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Albemarle (ALB - Free Report) closed at $96.23 in the latest trading session, marking a -8.91% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.23%. Meanwhile, the Dow experienced a rise of 0.72%, and the technology-dominated Nasdaq saw an increase of 1.86%.
Heading into today, shares of the specialty chemicals company had gained 19.91% over the past month, outpacing the Basic Materials sector's loss of 1.98% and the S&P 500's gain of 2.45%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 5, 2025. The company's earnings per share (EPS) are projected to be -$0.92, reflecting a 40.65% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.29 billion, down 4.64% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.59 per share and a revenue of $5.02 billion, representing changes of +32.05% and -6.66%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Albemarle. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.95% higher. Currently, Albemarle is carrying a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 232, positioning it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Albemarle (ALB) Stock Slides as Market Rises: Facts to Know Before You Trade
Albemarle (ALB - Free Report) closed at $96.23 in the latest trading session, marking a -8.91% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.23%. Meanwhile, the Dow experienced a rise of 0.72%, and the technology-dominated Nasdaq saw an increase of 1.86%.
Heading into today, shares of the specialty chemicals company had gained 19.91% over the past month, outpacing the Basic Materials sector's loss of 1.98% and the S&P 500's gain of 2.45%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 5, 2025. The company's earnings per share (EPS) are projected to be -$0.92, reflecting a 40.65% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.29 billion, down 4.64% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.59 per share and a revenue of $5.02 billion, representing changes of +32.05% and -6.66%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Albemarle. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.95% higher. Currently, Albemarle is carrying a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 232, positioning it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.